This is a study that evaluates the effect of mebufotenin (5-MeO-DMT), a fast-acting psychoactive molecule (peak effect within minutes and duration <1 hour), as a treatment for treatment-resistant depression (non-response to more than two antidepressants).<\/p>\n
The study is a randomized clinical trial with 40 patients who received mebufotenin and 41 who received placebo.<\/p>\n
The results show a high efficacy of the treatment (more than a 15-point reduction on a 60-point scale compared to placebo) as early as two hours after administration. The effect was maintained one week later.<\/p>\n
In addition, nearly 60% of patients achieved remission of depression (minimal symptoms) in the treatment group, compared to 0% in the placebo group.<\/p>\n
No serious adverse effects were observed; those reported were mild to moderate and transient.<\/p>\n
Limitations<\/strong><\/p>\n Mebufotenin is administered by inhalation, requires supervision, and produces a psychedelic effect that may be distressing for many people, making prior preparation and professional supervision necessary.<\/p>\n Participation in the study requires discontinuation of antidepressant treatment for at least two weeks, which may lead to clinical worsening and potentially amplify the observed treatment effect.<\/p>\n The response lasts for one week after a single administration (it is not a daily treatment). However, in medium- to long-term follow-up (six months), patients experience depressive relapses, most of which are resolved with re-administration (87% remain in remission after additional doses; these results will be published in another article).<\/p>\n Blinding effect: although the study is randomized, the psychedelic effect is difficult to conceal. The placebo does not produce perceptual changes (sensory alterations, ego changes, or mystical experiences), so blinding is limited.<\/p>\n Selection bias: participants know they may receive a psychedelic, which may introduce expectation bias (greater placebo effect).<\/p>\n Conclusions<\/strong><\/p>\n This is an effective, rapid treatment without serious adverse effects.<\/p>\n It has a clearly different profile compared to classical antidepressants: rapid effect, no need for daily administration, and efficacy within hours rather than weeks.<\/p>\n The main limitation is the induction of transient psychedelic effects, which requires supervised administration by trained professionals, making at-home use unfeasible.<\/p>\n In this study, psychotherapy was not administered, which could potentially increase the treatment\u2019s effectiveness.<\/p>\n The use of psychedelics opens a very promising therapeutic avenue for treatment-resistant depression.<\/p>\n","protected":false},"excerpt":{"rendered":"This is a study that evaluates the effect of mebufotenin (5-MeO-DMT), a fast-acting psychoactive molecule (peak effect within…\n","protected":false},"author":2,"featured_media":406160,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[274],"tags":[164,18,135,19,17,462,167,33145],"class_list":["post-406159","post","type-post","status-publish","format-standard","has-post-thumbnail","category-medication","tag-depression","tag-eire","tag-health","tag-ie","tag-ireland","tag-medication","tag-mental-health","tag-psychedelics"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ie\/116299303103143399","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/406159","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/comments?post=406159"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/406159\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media\/406160"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media?parent=406159"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/categories?post=406159"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/tags?post=406159"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}